未登录

K

Kristina Larsson

department of neurobiology, care sciences and society, division of physiotherapy, karolinska institutet, stockholm, sweden

H指数:23

被引数:1,792

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Relating movement behaviours and non-motor characteristics in people with Parkinson's disease: A compositional data analysis approach

探讨帕金森病患者运动行为与非运动特征的关系：一种组合数据分析方法

Journal of Parkinson’s Disease

IF0

2025-10-070

OA

What Is Rare and What Is Orphan? A Guide to the Regulatory Terminology

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2024-09-171

PRE

Predictors associated with an increase in daily steps among people with prediabetes or type 2 diabetes participating in a two-year pedometer intervention

BMC PUBLIC HEALTH

IF3.6

2024-05-111

OAAI

The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal Products

MOLECULAR THERAPY

IF12

2023-12-017

OAAI

P10-11 The effect of a pedometer-based intervention across two years, in people with type 2 diabetes and prediabetes-a compositional data analysis

EUROPEAN JOURNAL OF PUBLIC HEALTH

IF3.9

2022-08-290

OAAI

Lifestyle behaviors in Swedish university students before and during the first six months of the COVID-19 pandemic: a cohort study

BMC PUBLIC HEALTH

IF3.6

2022-06-166

OAAI

Effects of a three-armed randomised controlled trial using self-monitoring of daily steps with and without counselling in prediabetes and type 2 diabetes-the Sophia Step Study

INTERNATIONAL JOURNAL OF BEHAVIORAL NUTRITION AND PHYSICAL ACTIVITY

IF5.5

2021-09-0813

OAAI

Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit-The EU Regulator's Perspective

FRONTIERS IN MEDICINE

IF3

2021-08-273

OA

Regulatory Standards in Orphan Medicinal Product Designation in the EU

FRONTIERS IN MEDICINE

IF3

2021-06-259

OAAI

Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations

DRUG DISCOVERY TODAY

IF7.5

2020-07-0115

OAAI

Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseases

DRUG DISCOVERY TODAY

IF7.5

2020-02-015

OAAI

Therapies for rare diseases: therapeutic modalities, progress and challenges ahead (vol 47, pg 1206, 2019)

治疗罕见病: 治疗方式，进展和未来的挑战 (第47卷，1206页，2019)

NATURE REVIEWS DRUG DISCOVERY

IF101.8

2020-01-080

OAAI

Therapies for rare diseases: therapeutic modalities, progress and challenges ahead

罕见病的治疗: 治疗方式、进展与挑战

NATURE REVIEWS DRUG DISCOVERY

IF101.8

2019-12-13212

OAAI

Criterion validity and test-retest reliability of SED-GIH, a single item question for assessment of daily sitting time

BMC PUBLIC HEALTH

IF3.6

2019-01-0518

OAAI

Recommendations for the design of small population clinical trials

对小群体临床试验设计的建议

ORPHANET JOURNAL OF RARE DISEASES

IF3.5

2018-11-0683

OAAI

Defining orphan conditions in the context of the European orphan regulation: challenges and evolution

NATURE REVIEWS DRUG DISCOVERY

IF101.8

2018-09-125

PREAI

Establishing rarity in the context of orphan medicinal product designation in the European Union

DRUG DISCOVERY TODAY

IF7.5

2018-03-019

PREAI

Nonclinical data supporting orphan medicinal product designations: lessons from rare neurological conditions

DRUG DISCOVERY TODAY

IF7.5

2018-01-0110

PREAI

Demonstrating significant benefit of orphan medicines: analysis of 15 years of experience in Europe

DRUG DISCOVERY TODAY

IF7.5

2018-01-0116

PREAI

Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe

FRONTIERS IN MEDICINE

IF3

2017-05-1623

OAAI